采纳股份：关于对外投资收购股权进展暨完成股权变更登记的公告

Core Viewpoint - The company has approved the acquisition of a 70% stake in Jiangxi Fenglin Medical Technology Co., Ltd. for RMB 21 million, which will make Jiangxi Fenglin a subsidiary included in the company's consolidated financial statements [2]. Group 1 - The company held its 18th meeting of the third board of directors on December 22, 2025, where the investment acquisition proposal was approved [2]. - The acquisition will result in Jiangxi Fenglin becoming a controlling subsidiary of the company [2]. - The company has received the change registration certificate and shareholder register from Jiangxi United Registration and Settlement Co., Ltd., confirming the completion of the equity change registration [2].